GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

Home・Listă Acțiuni・Ocugen Inc

Ocugen Inc

Închisă

1.79 3.47

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.78

Maxim

1.79

Indicatori cheie
By Trading Economics
Venit	2.3M -18M
Vânzări	-1.9M -193K
Marjă de profit	9,174.093
Angajați	116
EBITDA	1.5M -16M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+566.49% upside

Dividende
By Dow Jones
Următoarele câștiguri	8 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-8.7M 626M
Deschiderea anterioară	-1.68
Închiderea anterioară	1.79

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

0.6818 / 0.74 Suport & Rezistență

Ocugen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 mai 2026, 23:43 UTC

Evenimente importante

New Zealand's Unemployment Rate Falls in 1Q

5 mai 2026, 23:20 UTC

Acțiuni populare

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 mai 2026, 21:48 UTC

Câștiguri

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 mai 2026, 21:05 UTC

Achiziții, Fuziuni, Preluări

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 mai 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 mai 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 mai 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5 mai 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 mai 2026, 22:08 UTC

Câștiguri

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 mai 2026, 22:07 UTC

Câștiguri

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:48 UTC

Câștiguri

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 mai 2026, 21:48 UTC

Câștiguri

Pan American Silver 1Q Rev $1.2B >PAAS

5 mai 2026, 21:42 UTC

Câștiguri

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:38 UTC

Câștiguri

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:30 UTC

Câștiguri

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:29 UTC

Câștiguri

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:26 UTC

Câștiguri

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 mai 2026, 21:25 UTC

Câștiguri

Alcon Inc. 1Q EPS 39c >ALC.EB

5 mai 2026, 21:25 UTC

Câștiguri

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 mai 2026, 21:24 UTC

Câștiguri

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:18 UTC

Câștiguri

Mistras Backs 2026 Rev $730M-$750M >MG

5 mai 2026, 21:17 UTC

Câștiguri

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 mai 2026, 21:15 UTC

Câștiguri

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 mai 2026, 21:12 UTC

Câștiguri

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 mai 2026, 21:11 UTC

Câștiguri

SSR Mining 1Q Rev $581.8M >SSRM

5 mai 2026, 21:10 UTC

Câștiguri

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 mai 2026, 21:10 UTC

Câștiguri

SSR Mining 1Q EPS $1.16 >SSRM

5 mai 2026, 21:08 UTC

Câștiguri

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:01 UTC

Câștiguri

Intact Financial 1Q EPS C$4.12 >IFC.T

5 mai 2026, 21:01 UTC

Acțiuni populare

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Comparație

Modificare preț

Ocugen Inc Așteptări

Obiectiv de preț

By TipRanks

566.49% sus

Prognoză pe 12 luni

Medie 12.33 USD 566.49%

Maxim 22 USD

Minim 8 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOcugen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 6 analiști care au acordat evaluări ale acțiunilor Ocugen Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.6818 / 0.74Suport & Rezistență

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.